PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 206 filers reported holding PDL BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is 0.15 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,432,000 | -37.6% | 675,286 | -1.4% | 0.00% | -33.3% |
| Q3 2016 | $2,295,000 | +6.2% | 685,096 | -0.4% | 0.00% | 0.0% |
| Q2 2016 | $2,160,000 | +5.4% | 687,978 | +11.8% | 0.00% | 0.0% |
| Q1 2016 | $2,050,000 | -5.8% | 615,620 | +0.1% | 0.00% | 0.0% |
| Q4 2015 | $2,177,000 | -29.4% | 614,958 | +0.3% | 0.00% | -25.0% |
| Q3 2015 | $3,085,000 | -21.3% | 613,242 | +0.6% | 0.00% | -20.0% |
| Q2 2015 | $3,919,000 | +24.6% | 609,426 | +36.3% | 0.01% | +25.0% |
| Q1 2015 | $3,146,000 | -7.3% | 447,124 | +1.6% | 0.00% | 0.0% |
| Q4 2014 | $3,394,000 | +2.7% | 440,177 | -0.5% | 0.00% | -20.0% |
| Q3 2014 | $3,305,000 | -22.3% | 442,480 | +0.7% | 0.01% | -16.7% |
| Q2 2014 | $4,251,000 | +15.2% | 439,201 | -1.1% | 0.01% | +20.0% |
| Q1 2014 | $3,690,000 | +12.7% | 443,990 | +14.4% | 0.01% | 0.0% |
| Q4 2013 | $3,275,000 | +3.1% | 387,990 | -2.7% | 0.01% | 0.0% |
| Q3 2013 | $3,177,000 | +10.6% | 398,593 | +7.1% | 0.01% | 0.0% |
| Q2 2013 | $2,873,000 | – | 372,104 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |